Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.

ABSTRACT:

Background

Genomic analysis of circulating tumor DNA (ctDNA) is increasingly incorporated into the clinical management of patients with advanced cancer. Beyond tumor profiling, ctDNA analysis also can enable calculation of circulating tumor fraction (TF), which has previously been found to be prognostic. While most prognostic models in metastatic cancer are tumor type specific and require significant patient-level data, quantification of TF in ctDNA has the potential to serve as a pragmatic, tumor-agnostic prognostic tool.

Patients and methods

This study utilized a cohort of patients in a nationwide de-identified clinico-genomic database with metastatic castration-resistant prostate cancer (mCRPC), metastatic breast cancer (mBC), advanced non-small-cell lung cancer (aNSCLC),

SUBMITTER: Reichert ZR 

PROVIDER: S-EPMC9805517 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature